Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA [0.03%]
美国长效注射型二甲双胍（400毫克，每月一次）在I型双向情感障碍疾病中的成本效益分析
Margarida Augusto,Mallik Greene,Maëlys Touya et al.
Margarida Augusto et al.
Aim: To evaluate the cost-effectiveness of aripiprazole once-monthly 400/300 mg (AOM 400) in maintenance monotherapy treatment of bipolar I disorder (BP-I). ...
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA [0.03%]
美国成人I型双相情感障碍患者使用长效注射剂阿立哌唑(400毫克，每月一次)的预算影响分析
Margarida Augusto,Mallik Greene,Maëlys Touya et al.
Margarida Augusto et al.
Aim: To estimate the budget impact (BI) of introducing aripiprazole once-monthly 400 mg/300 mg (AOM 400) in the maintenance monotherapy treatment of bipolar I disorder versus long-acting injectables, oral antipsychotics a...
An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity [0.03%]
BLM静脉与皮下给药在高疾病活动度系统性红斑狼疮患者中疗效的间接比较研究
Sulabha Ramachandran,Daniel Parks,Milena Kurtinecz et al.
Sulabha Ramachandran et al.
Aim: To compare the efficacy of intravenous (IV) and subcutaneous (SC) belimumab plus standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus and high disease activity (HDA). ...
Clinical and economic benefits of advanced microplegia delivery system in cardiac surgery: evidence from 250 hospitals [0.03%]
高级微导管输送系统在心脏手术中的临床和经济效益证据：来自250家医院的证据
Marc W Gerdisch,Scott Robinson,Guy David et al.
Marc W Gerdisch et al.
Aim: Determine the impact of a second generation microplegia delivery system (MPS2) compared with traditional cardioplegia. Materials & methods: Multivariable difference-in-differences analysis using fixed effects was per...
Observational Study
Journal of comparative effectiveness research. 2018 Jul;7(7):673-683. DOI:10.2217/cer-2018-0011 2018
Analysis of indirect treatment comparisons in national health technology assessments and requirements for industry submissions [0.03%]
国家卫生技术评估中的间接治疗比较分析及对企业的相关要求
Ischa J Es-Skali,John Spoors
Ischa J Es-Skali
Aim: To determine the preferred methodologies of health technology assessment (HTA) agencies across Europe, Canada and Australia to ascertain acceptance of indirect treatment comparisons (ITC) as a source of comparative evidence. Method: A ...
Therapeutic approach for patients with venous thromboembolism attended in emergency departments during routine clinical practice: the EDITH study [0.03%]
急诊科门诊静脉血栓栓塞症患者的治疗方案：EDITH研究
Pedro Ruiz-Artacho,Pascual Piñera,Albert Antolin et al.
Pedro Ruiz-Artacho et al.
Aim: To analyze treatment at discharge/follow-up of patients diagnosed with venous thromboembolism (VTE) in the emergency department (ED). Materials & met...
Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment [0.03%]
钇90玻璃微球选择性内放射治疗与传统非手术/介入治疗肝癌的生存期对比研究
David Thayer,Christopher Noda,Resmi Charalel et al.
David Thayer et al.
Aim: To compare the overall survival (OS) and liver cancer-specific survival of advanced-stage hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with those who received nonoperati...
Comparison of therapies in lumbar degenerative disc disease: a network meta-analysis of randomized controlled trials [0.03%]
腰椎退行性疾病的治疗比较：随机对照试验的网状meta分析
Jack Zigler,Nicole Ferko,Chris Cameron et al.
Jack Zigler et al.
Aim: To compare the efficacy and safety of total disc replacement, lumbar fusion, and conservative care in the treatment of single-level lumbar degenerative disc disease (DDD). ...
Patricia Guyot,Wei Cheng,Gabriel Tremblay et al.
Patricia Guyot et al.
Aim: For dichotomous outcomes, odds ratio (OR) is one of the usual summary measures of indirect treatment comparison. A corresponding number needed to treat (NNT) estimate may facilitate understanding of the treatment eff...
Economic and organizational impact of the changing hospital funding practices of erythropoiesis-stimulating agents on the management of care of dialysis patients in France [0.03%]
法国医院促红细胞生成素刺激剂(EPO)资金政策变化对透析患者医疗管理的经济和组织影响
Carole Therasse,Isabelle Fusier,Anne-Laure Cordonnier et al.
Carole Therasse et al.
Aim: Erythropoiesis-stimulating agents (ESAs) are particularly used to treat dialysis patients suffering from anemia due to renal failure. Since March 2014, ESAs have no longer been funded on top-of-diagnosis-related grou...